4 news items
Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
GOSS
7 May 24
in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications
GOSS
6 May 24
, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995
Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine
GOSS
3 May 24
Litigation Reform Act of 1995
Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
GOSS
5 Mar 24
Securities Litigation Reform Act of 1995
- Prev
- 1
- Next